Retatrutide on Reddit: what the forums report, checked against the trials

By Retatrutide Risk editorial team. Published September 21, 2026. Sources at the end of the page.

Reddit is where most people first read a first-person account of retatrutide. The subreddits devoted to peptides and to GLP-1 drugs contain thousands of posts describing weight loss, side effects, sourcing and dosing of "reta". Those posts are useful for one thing: learning what questions people have. They are not useful for answering them. This page takes the recurring themes from those forums and sets each one against what the registered trials have published.

First, what forum posters are actually using

Almost every forum report concerns a lyophilized powder bought from an online vendor, reconstituted at home and injected without medical supervision. That product has no established purity, no established concentration and no batch traceability comparable to a clinical trial supply. When a poster writes "I am on 4 mg", the true dose depends on the vendor's accuracy, the reconstitution arithmetic and the syringe reading. This is the first reason forum outcomes cannot be compared directly with trial outcomes, and it is the reason this page never cites a forum figure as data.

Theme 1: "The weight loss is faster than anything else"

This is the most frequent claim, and it is broadly consistent with the trials, with two caveats.

The phase 2 obesity trial reported mean weight change at 24 weeks of -7.2% (1 mg), -12.9% (4 mg), -17.3% (8 mg) and -17.5% (12 mg), against -1.6% on placebo. At 48 weeks the 12 mg arm reached -24.2%. In the 80-week phase 3 TRIUMPH-1 trial, the company reported -28.3% at 12 mg. These are large numbers by the standards of the drug class.

The first caveat is that these are means of groups. At 48 weeks in phase 2, 83% of participants on 12 mg had lost at least 15% of their body weight, which means 17% had not. Individual posts describing exceptional loss are reporting one point in a distribution.

The second caveat is timescale. Forum posts frequently report several kilograms lost in the first two weeks. The trials measured at 24 and 48 weeks (phase 2) or 68 to 80 weeks (phase 3); early rapid loss in an unmonitored setting also reflects fluid, reduced food intake from nausea, and reconstitution errors that deliver more than the intended dose.

Theme 2: nausea, vomiting and "food aversion"

Consistent with the trials. In the phase 2 obesity trial, gastrointestinal events were the most common adverse events, were dose-related, were mostly mild to moderate, and were partially mitigated with a 2 mg rather than 4 mg starting dose. In TRIUMPH-1, nausea was reported by 28.6% (4 mg), 38.4% (9 mg) and 42.4% (12 mg) versus 14.8% on placebo, and vomiting by 10.6%, 22.8% and 25.3% versus 4.8%.

What the forums add that the trials cannot confirm is the connection between fast escalation and worse nausea. The phase 2 type 2 diabetes trial is the closest evidence: the 8 mg arm that started at 4 mg reported the highest rate of gastrointestinal events of any arm (12 of 24 participants, 50%). The abstract does not give the figure for the 8 mg arm that started at 2 mg, but the obesity trial states that the lower starting dose partially mitigated these events. Forum escalation is typically faster than either schedule.

Theme 3: resting heart rate is up

Consistent with the trials, and under-appreciated on the forums. The phase 2 obesity paper states that dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. Posters who track heart rate with a watch often report an increase of several beats per minute in the first months; the published abstract does not give the magnitude per arm, so a forum figure cannot be checked against it. What the trials cannot say yet is whether this matters: the cardiovascular outcomes trial (TRIUMPH-Outcomes, NCT06383390) is not expected to finish before 2029. See the heart rate article.

Theme 4: fatigue, "no energy", low mood

Frequently reported, not addressed by the published abstracts. Fatigue is not among the adverse events listed in the phase 2 abstracts or the phase 3 announcements, which list gastrointestinal events, dysesthesia and urinary tract infections. That does not mean fatigue did not occur in the trials; abstracts and announcements list only the most frequent events. It means the published record neither confirms nor refutes the forum reports. Reduced food intake of the magnitude that produces 25% weight loss is itself a plausible cause of fatigue, independent of any drug effect.

Theme 5: tingling, burning skin, sensitivity to touch

Confirmed by phase 3, and one instance where the forums noticed a signal before the company announcements named it. Dysesthesia was reported in TRIUMPH-1 at 5.1% (4 mg), 12.3% (9 mg) and 12.5% (12 mg) versus 0.9% on placebo, and in TRIUMPH-4 at 8.8% (9 mg) and 20.9% (12 mg) versus 0.7%. Lilly describes the events as generally mild and rarely leading to discontinuation. The mechanism has not been published.

Theme 6: "It fixed my fatty liver"

Partially supported. The phase 2a liver substudy (Sanyal et al., Nature Medicine 2024) enrolled 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat. At 24 weeks the mean relative change in liver fat was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg) and -82.4% (12 mg) versus +0.3% on placebo, and normal liver fat (below 5%) was reached by 27%, 52%, 79% and 86% of participants versus 0% on placebo. Liver fat was measured by imaging under a protocol. A forum poster reporting improved liver enzymes is reporting something related but not identical.

Theme 7: dosing charts, microdosing and cycles

Not supported by any trial. Forum dosing conventions include starting at fractions of a milligram, escalating weekly, "cycling" on and off, and combining retatrutide with other peptides. The registered trials used fixed maintenance doses of 0.5 to 12 mg reached by a stepwise escalation (2, 4, 8, 12 mg), administered continuously for 36 to 104 weeks, with no combination products. The dosage article sets out every arm. No published trial has tested intermittent use, and nothing is published on what happens to weight after stopping.

Theme 8: which vendor is "legit"

Outside the scope of evidence. Vendor comparisons on forums are based on user-submitted certificates of analysis, personal experience and reputation, all of which can be manipulated. The trials used product manufactured by Lilly. The where-to-buy article describes what a certificate of analysis should contain and the recognizable signs of a fraudulent listing, without endorsing any seller.

The themes in one table

Why forum experience cannot be generalized

• Selection. People who post are those with strong results or strong side effects. The median experience goes unreported.
• No control group. Every trial figure above is measured against placebo. A forum has no placebo arm, so the 2.1% weight loss that placebo participants achieved over 48 weeks in phase 2 is invisibly folded into every forum success story.
• No exclusion criteria. Trials excluded people with conditions that make the drug riskier. Forum posters include them.
• No monitoring. Trial participants had scheduled visits, laboratory tests and adverse-event reporting. A forum poster who develops a serious problem may stop posting rather than report it.
• Unknown product. The dose, purity and stability of a grey-market vial are unknown to the poster.

How to read a retatrutide thread

Treat each post as a question to check against the sources listed at the bottom of this page, not as an answer. If a claim is consistent with the trials, the trials are the citation, not the post. If a claim is not addressed by the trials, it is unverified, and the honest word for it is anecdote. The side effects article and the results article contain every published figure needed for that check.